bluuebunny/crossref_metadata_2025_split huggingface dataset:
1765-P: Direct ß-Cell Effects of miR-6727-3p, an miRNA Related to Improved ß-Cell Function in Humans
Authors: ZRAIKA SAKENEH , BARROW BREANNE , ENQUOBAHRIE DANIEL , BAMMLER THEO K. , MACDONALD JAMES , SRINOUANPRACHANH SENGKEO , CHUEN GARY CHAN KWUN , BOYKO EDWARD J. , KAHN STEVEN E. , WANDER PANDORA 
Published: June 2023

Most people with type 2 diabetes (T2D) have limited improvement in β-cell function with glucose-lowering treatment; but we know little about contributing factors. Plasma miRNAs may reflect or predict treatment response at the level of the β cell. In youth treated with insulin glargine followed by metformin in the Restoring Insulin Secretion Study, we found that miR-6727-3p was positively associated with treatment response. Thus, we sought to determine whether miR-6727-3p has a direct effect on islets to improve insulin secretion and decrease cell death under T2D conditions. C57BL/6 mouse islets were treated for 48 h with 11.1 mM glucose (considered “normal” for mouse islets) or 25 mM glucose + 0.5 mM palmitate (“T2D”) in the presence of 5 nM miR-6727-3p mimic or miR-scramble. Thereafter, we assessed glucose-stimulated insulin secretion (GSIS) and islet cell death. T2D conditions resulted in elevated basal and reduced GSIS (Table). Regardless of condition, miR-6727-3p had no effect to change basal or GSIS. As expected, cell death increased in islets cultured in T2D vs normal conditions, but surprisingly, miR-6727-3p further exacerbated cell death under both conditions. Together, these data suggest miR-6727-3p may not alter β-cell function but that it may be deleterious to β-cell survival. Moreover, higher levels of plasma miR-6727-3p in responders are likely unrelated to treatment response.

Disclosure
S.Zraika: None. P.Wander: None. B.Barrow: None. D.Enquobahrie: None. T.K.Bammler: None. J.Macdonald: None. S.Srinouanprachanh: None. K.Chan: None. E.J.Boyko: None. S.E.Kahn: Advisory Panel; Anji Pharmaceuticals, Bayer Inc., Boehringer Ingelheim Inc., Eli Lilly and Company, Merck & Co., Inc., Other Relationship; Novo Nordisk.

Funding
National Institutes of Health (R01DK132355)
229-OR: A Calibration Protocol for Continuous Glucose Monitor Accuracy in the ICU
Authors: BANN SEWON , HERCUS JESS C. , ATKINS PAUL , ALKHAIRY AREEJ , THOMPSON DAVID M. 
Published: June 2023

Guidelines now recommend inpatient continuous glucose monitor (CGM) use, assuming that it is sufficiently accurate due to its apparent safety. The FDA issued a non-objection letter for inpatient CGM use, but it is not yet officially approved for hospitals, including in the ICU. To further study CGM in the ICU, we tested the accuracy of the Dexcom G6 (G6) in 32 adults in a medical-surgical ICU in Vancouver, BC using a calibration protocol in 1035 matched CGM and arterial point-of-care (POC) pairs. Our first uncalibrated study had a mean absolute relative differential (MARD) of 13.24%, which barely meets the critical care expert recommendation of MARD &lt;14%. This study aims to show a higher accuracy can be achieved with a simple calibration protocol on Day 1, then none thereafter. The MARD for calibrated patients was 9.27%, significantly lower than 13.19% for uncalibrated patients (p&lt;0.001). Calibration also had excellent safety with 100% of values within Clarke Error Grid Zones A and B compared to 99.07% without calibration. Our protocol achieved the lowest MARD and safest Clarke Error Grid profile of any ICU study comparing CGM to standard of care arterial POC and well exceeds the critical care expert recommendations. Our large sample of heterogenous critically ill patients also reached comparable accuracy to the MARD of 9% for G6 in outpatients. We believe our calibration protocol will allow CGM to be used with sufficient accuracy in the ICU.

Disclosure
S.Bann: None. J.C.Hercus: None. P.Atkins: None. A.Alkhairy: None. D.M.Thompson: None.
249-OR: Predictors of Impaired Awareness of Hypoglycemia in Adults with Type 1 Diabetes
Authors: GIBB FRASER W. , STIMSON ROLAND H. , FORBES SHAREEN , DOVER ANNA R. 
Published: June 2023

Background: Impaired awareness of hypoglycemia (IAH) is associated with a substantially increased risk of severe hypoglycemia (SH) in type 1 diabetes. Risk factors for IAH are not well characterized in the modern context. We assessed associations with IAH in adults with type 1 diabetes.
Methods: Cross-sectional observational study. 782/2210 (35.4%) of people with type 1 diabetes attending a UK diabetes center completed a questionnaire with questions on hypoglycemia awareness and mental health. Data were also extracted for CGM metrics and additional clinical and demographic information.
Results: 54.1% of participants were men. Median age was 51 years and diabetes duration was 24 years. 27.0% were on CSII. 88.6% were using CGM. IAH (Gold score ≥ 4) was present in 21.3%. 10.0% had a hypoglycemia awareness threshold less than 3.0 mM (54mg/dl). 5.1% gave a recent history of severe hypoglycemia. IAH associations are presented in the table. PHQ-2 depression screen positive (HR 2.1, p = 0.009), socioeconomic deprivation (HR 1.8, p = 0.006) and female sex (HR 1.8, p = 0.002) were independently associated with IAH.
Discussion: IAH, as defined by elevated Gold Score, was associated with a near four-fold increased risk of SH. Psychological approaches to IAH have shown promise and these data highlight the importance of adequate mental health screening, especially in IAH.

Disclosure
F.W.Gibb: Advisory Panel; Abbott. R.H.Stimson: None. S.Forbes: None. A.R.Dover: Other Relationship; Abbott Diabetes.
528-P: Different Glycemic Responses in People with T1 or T2DM after Use of an Insulin Injection Supporting App
Authors: SIEBER JOCHEN , WIENBARG INKA , MAHONEY ED , HAAK THOMAS 
Published: June 2023

Lipohypertrophy, poor insulin injection technique and missed boluses are well-known issues in the management of diabetes but are sometimes overlooked. This study evaluated whether use of an app with digital training on correct injection routines, site rotation and injection related behaviors will improve glycemic control. Here, we present results of a post hoc analysis on CGM parameters. This was a prospective, open label study with patients on MDI (at least one basal and one bolus insulin injection), HbA1c ≥7% using an intermittent CGM device. A 4-week period without app use was followed by a 4-week period with the use of the app. Time below (&lt;70mg/dl), in (70-180mg/dl), above (&gt;180mg/dl) glycemic ranges, mean glucose, SD & CV were analyzed. 58 patients (37 male, 21 female) completed the study (mean age 52.0 ± 14.6y, diabetes duration 19.2 ± 12.5y, HbA1c 8.0 ± 0.8%, 35 T1DM, 23 T2DM). Overall (N=58), there were significant differences (p&lt;0.001) between baseline and intervention for mean glucose (190.2 (39.2) vs 186.0 (42.0)), time in range (49.9 (17.1) vs 52.6 (18.3)) and time &gt;180 mg/dl (48.2 (17.3) vs 45.4 (18.8)). No significant differences in % of values in hypoglycemia were observed. Table shows mean point estimates for differences from baseline for diabetes subgroups. The use of an insulin injection supporting app leads to improvements in glycemic measures with differences between people with T1DM & T2DM..

Disclosure
J.Sieber: Employee; Becton, Dickinson and Company, embecta, Stock/Shareholder; Becton, Dickinson and Company, embecta. I.Wienbarg: None. E.Mahoney: None. T.Haak: None.
780-P: Occurrence of Gastrointestinal (GI) Side Effects upon GLP-1 Receptor Agonist (GLP-1RA) Initiation with Concomitant Metformin Use
Authors: KLEIN KLARA R. , CLEMMENSEN KIM K.B. , FONG EDWIN , OLSEN SØREN , ABRAHAMSEN TRINE J. , LINGVAY ILDIKO 
Published: June 2023

GI symptoms are common side effects reported with both GLP-1RA and metformin use, yet these agents are often prescribed in combination. GLP-1RA are initiated at low dose and escalated to minimize the occurrence of GI side effects. Still, most treatment related GI adverse events occur during the dose titration period. We evaluated whether concomitant metformin use increases the rate of GI adverse events during the GLP-1RA titration period.
Using data from 4 clinical trials, LEADER (1.8 mg liraglutide), STEP-2 (1/2.4 mg semaglutide), SUSTAIN-6 (0.5/1 mg semaglutide), and PIONEER-6 (14 mg oral semaglutide), we compared the incidence of GI adverse events during the titration period defined as the expected time to steady state of the respective drug (3 weeks-5 months, see table) in participants with and without concomitant metformin use.
Of the 16,996 participants in these trials, 12,928 (76%) were treated with metformin. The percent of participants who developed new or serious GI adverse events during the titration period was similar across those with or without concomitant metformin use in each group (GLP-1RA or placebo) in all trials (Table). The occurrence of individual GI event (nausea, vomiting, diarrhea, and constipation) was also similar (data not shown).
In summary, concomitant metformin use does not increase the occurrence of GI symptoms during early GLP-1RA treatment.

Disclosure
K.R.Klein: None. K.K.B.Clemmensen: Employee; Novo Nordisk A/S, Stock/Shareholder; Novo Nordisk A/S. E.Fong: Employee; Novo Nordisk A/S. S.Olsen: None. T.J.Abrahamsen: Employee; Novo Nordisk A/S, Stock/Shareholder; Novo Nordisk A/S, Genmab A/S. I.Lingvay: Advisory Panel; Novo Nordisk A/S, Lilly Diabetes, Boehringer-Ingelheim, Sanofi, Consultant; Carmot Therapeutics, Inc., Merck Sharp & Dohme Corp., Janssen Scientific Affairs, LLC, Pfizer Inc., Intercept, Intarcia, Valeritas, TargetRWE, Shionogi, Zealand Pharma, Structure, Bayer, Research Support; Novo Nordisk A/S, Boehringer-Ingelheim.
835-P: First-in-Human Duodenal Endoscopic Recellularization via Electroporation Therapy for Type 2 Diabetes—An Interim Report
Authors: YI YUAN CHENG , SARTORETTO ADRIAN , HOLT BRONTE , CAMERON GEORGINA , MARINOS GEORGE , NAPIER-FLOOD FIONA E. , ABU DAYYEH BARHAM K. , O'NEAL DAVID N. 
Published: June 2023

Background: We evaluated the feasibility and safety of endoscopic re-cellularization via electroporation therapy (ReCET) (Endogenex. Plymouth, MN) in restoring impaired duodenal signaling adversely impacting glucose control in type 2 diabetes (T2D).
Method: We enrolled 30 adults with T2D: duration ≤10 years; HbA1c 7.5-11.0%; BMI of 24-40 kg/m2; C-peptide ≥333pmol/L; 1-4 non-insulin glucose-lowering medications (GLMs) at stable dose. Post-procedure GLMs were unchanged. Primary endpoint: Device or procedure-related serious adverse events (SAEs). Secondary endpoints: Changes in metabolic parameters at 24W.
Results: The first 12 participants received single energy (Single Tx) then 18 received double energy application (Double Tx) with no device/procedure-related SAEs. Forty-five adverse events were reported in 23/30 participants (sore throat [17/30]; transient diarrhea [9/30]) and 80% were mild.
HbA1c reduction at 24W was greater with double vs. single Tx (p&lt;0.05). For double Tx vs. baseline: FPG was 7.5±1.7 mmol/L vs. 9.8±2.2 mmol/L (p&lt;0.01), HOMA-IR 4.5±3.6 vs. 7.4±3.3 (p&lt;0.01), Time-in-range 79.4±18.8 % vs. 59.0±24.2% (p&lt;0.01), triglyceride 2.0±1.2mmol/L vs. 2.9±1.9mmol/L (P&lt;0.05) and Δweight -5.1%±4.1% (p&lt;0.01).
Conclusions: Our data suggest that ReCET is safe and associated with clinically meaningful changes in metabolic control in T2D patients on GLMs.

Disclosure
C.Yuan: None. A.Sartoretto: Advisory Panel; Bariatek, Research Support; Endogenex, Erbe Electromedizin GMBH, Speaker's Bureau; Pfizer Inc., Stock/Shareholder; Apollo Endosurgery. B.Holt: None. G.Cameron: None. G.Marinos: None. F.E.Napier-flood: None. B.K.Abu dayyeh: Advisory Panel; Endogenex, Consultant; Apollo Endosurgery, Boston Scientific Corporation, Medtronic, Research Support; USGI, Endogastric Solutions. D.N.O'neal: None.
91-LB: COVALENT-111, a Phase 1/2 Trial of BMF-219, a Covalent Menin Inhibitor, in Patients with Type 2 Diabetes Mellitus—Preliminary Results
Authors: RODRIGUEZ JOSE E. , ABITBOL ALEXANDER , ABUZGAYA FATHI , PEREZ CESAR , MOURYA SANCHITA , MUNNEKE BRIAN , MORRIS STEPHAN W. , BUTLER THOMAS 
Published: June 2023

Type 2 Diabetes Mellitus (T2DM) is characterized by impaired glycemic control caused by insulin resistance and progressive beta cell failure. Menin, a scaffold protein, drives beta cell proliferation when inhibited. We have reported BMF-219, an oral covalent menin inhibitor, elicits durable glycemic control following a short treatment in a ZDF Rat model. COVALENT-111, a randomized, double-blind, placebo-controlled study is evaluating BMF-219 in healthy adults and adults with T2DM diagnosed ≤15 yrs (NCT05731544). Here we report initial results from the first cohort of T2DM patients treated with BMF-219. Patients with poor glycemic control (HbA1C ≥7%) on their current antidiabetic regimen were enrolled. Twelve patients were randomized 5:1 (10 BMF-219, 2 placebo) to receive 100 mg QD for 4 weeks while continuing their existing treatment. BMF-219 was well tolerated; no subjects discontinued treatment or exited the trial during the 4-week treatment and all subjects continue in follow-up to assess durability of the treatment effect. There were no dose reductions, SAEs, or severe AEs. All TRAEs were mild and observed in 3 of 12 subjects. No subjects showed symptomatic hypoglycemia. These data demonstrate preliminary proof of concept for the novel disease-modifying effect of BMF-219 in T2DM. Enrollment is ongoing at higher doses; additional follow-up data will be presented.

Disclosure
J. E. Rodriguez: None. A. Abitbol: Advisory Panel; Abbott Diabetes, Lilly Diabetes, Dexcom, Inc., Novo Nordisk Canada Inc., Janssen Pharmaceuticals, Inc., Research Support; Abbott Diabetes, Lilly Diabetes, Zucara Therapeutics, Novo Nordisk Canada Inc., Moderna, Inc., Senseonics, Speaker's Bureau; Boehringer Ingelheim (Canada) Ltd., Lilly Diabetes, Amgen Canada, Dexcom, Inc., Novo Nordisk Canada Inc., HLS Therapeutics Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Sanofi. F. Abuzgaya: None. C. Perez: None. S. Mourya: Employee; Biomea Fusion, Inc. B. Munneke: Employee; Biomea Fusion, Inc., Corvus Pharmaceuticals. S. W. Morris: Employee; Biomea Fusion, Inc. T. Butler: Board Member; Biomea Fusion, Inc., Employee; Biomea Fusion, Inc., Stock/Shareholder; Biomea Fusion, Inc.

Funding
Not applicable
Benefits and challenges of creating veterinary antibiograms for empiric antimicrobial selection in support of antimicrobial stewardship and advancement of one-health goals
Authors: Burbick Claire R. , Fajt Virginia R. , Frey Erin , Fritz Heather , Goodman Laura B. , Lorenz Catherine , Lubbers Brian V. , Marshall Edith , Rankin Shelley C. , Silva Marissa 
Published: June 2023

Abstract
Antibiograms are important tools for antimicrobial stewardship that are often underutilized in veterinary medicine. Antibiograms summarize cumulative antimicrobial susceptibility testing (AST) data for specific pathogens over a defined time period; in veterinary medicine, they are often stratified by host species and site of infection. They can aid practitioners with empiric therapy choices and assessment of antimicrobial resistance trends within a population in support of one-health goals for antimicrobial stewardship. For optimal application, consideration must be given to the number of isolates used, the timeframe of sample collection, laboratory analytical methodology, and the patient population contributing to the data (eg, treatment history, geographic region, and production type). There are several limitations to veterinary antibiograms, including a lack of breakpoint availability for bacterial species, a lack of standardization of laboratory methodology and technology for culture and AST, and a lack of funding to staff veterinary diagnostic laboratories at a level that supports antibiogram development and education. It is vital that veterinarians who use antibiograms understand how to apply them in practice and receive relevant information pertaining to the data to utilize the most appropriate antibiogram for their patients. This paper explores the benefits and challenges of developing and using veterinary antibiograms and proposes strategies to enhance their applicability and accuracy. Further detail regarding the application of veterinary antibiograms by privately practicing clinicians is addressed in the companion Currents in One Health article by Lorenz et al (JAVMA, September 2023).
Can the war in Ukraine thwart the green agricultural transformation in the EU? Political economy considerations regarding the case of Germany
Authors: Wandel Jürgen 
Published: June 2023

Abstract
The war in Ukraine threatens global food security. At the same time, the European Union (EU) plans to advance the green transformation of its agro-food sector, which implies lower agricultural output. Relying on the political economy literature, this study examines if the war can thwart the greening ambitions for EU’s agro-food sector. For this, it explores to what extent the war represents an external event that is large enough to change policy preferences and reviews the positions of major political actors who shape agricultural policy on the EU level and in member states regarding the case of Germany, where the ambition for the green transformation of the economy is particularly strong. It is shown that, for the time being, the war does not impede EU’s greening aspirations. Instead, the major political actors play for time, hoping to forward the green transformation after the end of the war.
The Discipline of Historical Liturgics in Russia: From «Unhappy Step-daughter» to Full-fledged Scholarly Discipline
Authors: Dashevskaya Zoya 
Published: June 2023

Abstract
The birth of liturgical research in Russia is a phenomenon that deserves careful study. The development of liturgical studies took place mainly in the Theological (Spiritual) Academies of St. Petersburg, Moscow, Kyiv and Kazan. The publication of liturgical source materials was the first step towards the establishment of an independent scientific school of liturgical studies in Russia. Thanks to Nikolai Krasnoseltsev, Ivan Mansvetov, Alexei Dmitrievskij, Ivan Karabinov and other prominent liturgists, we have a number of outstanding treatises on the liturgy of the East and West, the Typicon, both of Greek and Russian liturgical traditions, the Sacramental rites and other orders grown out of use. At present, the considerable range of matters addressed in these studies is poorly recognized, although the hypotheses of Russian scholars and their gains in methodology anticipated some of the achievements of the liturgists in the second half of the 20th century.
Pengaruh rasio keuangan terhadap kesulitan keuangan pada perusahaan sektor consumer goods di BEI
Authors: Tjandra Catherine Christiana , Widjaja Indra 
Published: June 2023

The world is currently in financial distress due to the Covid-19 virus. That leads to a decrease in profit each year. Due to the intense competition, companies incur significant costs to remain competitive in their business. The purpose of this study is to measure company size in terms of liquidity, solvency, revenue growth, activity and financial hardship using IDX-listed companies in the consumer goods sector for the period 2017-2020. That was it using 30 companies, descriptive research and quantitative methods were used in this study. Targeted sampling is a sampling technique used in research. Use Eviews 12 to explore multiple regression analysis of data processing techniques. As a result, liquidity and activity have a significant positive impact, solvency has a significant negative impact, revenue growth has no significant negative impact, and firm size has a significant positive impact on financial distress. Therefore, financial indicators are an effective way to find out whether a company's financial condition is good or bad.
Kesulitan keuangan saat ini telah dirasakan oleh dunia dikarenakan adanya virus covid 19. Dimana menyebabkan adanya penurunan keuntungan pada setiap tahunnya. Adanya persaingan yang tinggi sehingga perusahaan mengeluarkan biaya yang tinggi untuk dapat unggul dalam persaingan usahanya. Tujuan dari penelitian ini untuk mengukur likuiditas, solvabilitas, pertumbuhan penjualan, aktivitas, dan ukuran perusahaan terhadap kesulitan keuangan dengan menggunakan perusahaan sektor consumer goods terdaftar dalam BEI periode 2017 – 2020. Dengan menggunakan 30 perusahaan, penelitian menggunakan penelitian deskriptif, metode kuantitatif. Purposive sampling menjadi teknik pengambilan sampel pada penelitian. Menggunakan Eviews 12 dengan melihat analisis regresi berganda untuk teknik pengolahan data. Hasil penelitian menunjukkan, likuiditas dan aktivitas berpengaruh signifikan positif, solvabilitas berpengaruh signifikan negatif, pertumbuhan penjualan tidak berpengaruh signifikan negatif, dan ukuran perusahaan tidak berpengaruh signifikan positif terhadap kesulitan keuangan. Untuk itu rasio keuangan menjadi cara yang efektif untuk mengetahui kondisi baik atau buruknya keuangan suatu perusahaan.
Analisis penerapan dan pengaruh Kaizen PDCA terhadap kinerja karyawan Bank Central Asia (Studi kasus pada kantor pusat PT BCA Tbk)
Authors: Sulistyani Ririn 
Published: June 2023

This study aims to determine the application of Kaizen PDCA (Plan, Do, Check, Action) to describe the obstacles that occur and how they affect the performance of employees at the BCA head office. The type of research used in this research is qualitative research. Information was collected through interviews and observational data. The technique used in data collection is purposive sampling in which the selected informants were people with adequate knowledge and experience of Kaizen with research needs. To test the validity of the data using triangulation. The results of this study are that Kaizen PDCA has been and is still running consistently. The main obstacle faced was the repeated presentation of PDCA project ideas due to unintegrated documentation. The application of the Kaizen PDCA work culture increases team engagement and the quality of teamwork that affects the performance of individuals and related teams.
Penelitian ini bertujuan untuk mengetahui penerapan Kaizen PDCA (Plan, Do , Check, Action) gambaran kendala yang terjadi serta bagaimana pengaruhnya terhadap kinerja karyawan di kantor pusat BCA. Jenis penelitian yang digunakan dalam penelitian ini adalah penelitian kualitatif. Informasi dikumpulkan melalui wawancara dan data hasil observasi. Teknik yang digunakan dalam pengumpulan data yaitu purposive sampling dimana informan yang dipilih merupakan orang dengan pengetahuan dan pengalaman mengenai Kaizen yang cukup dengan kebutuhan penelitian. Untuk menguji keabsahan data menggunakan triangulasi. Hasil penelitian ini yaitu bahwa Kaizen PDCA sudah dan masih berjalan konsisten. Kendala utama yang dihadapi yaitu presentasi ide projek PDCA yang berulang dikarenakan dokumentasi yang belum terintegrasi. Penerapan budaya kerja Kaizen PDCA meningkatkan team engagement dan kualitas kerja tim yang memengaruhi kinerja individu maupun tim terkait.